美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ALDX近 30 天 20 則 · 第 1 / 1 頁
- Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
- XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
- RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
- Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
- Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
- GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
- Definium Reports Second Phase III Success in Anxiety Disorder Program
- GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
- AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
- Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
- Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
- Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
- CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
- SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
- Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
- FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
- RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
- Here's Why You Should Add RNTX Stock to Your Portfolio Now
- AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。